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Summary Urokinase-type plasminogen activator (uPA) is a potentially important prognostic factor in breast cancer for identifying patients at
high risk of recurrence. This retrospective study assessed two enzyme-linked immunosorbent assay (ELISA) methods measuring uPA
antigen levels in 499 primary breast cancer cytosols. Both uPA methods were applied to cytosols used routinely for oestrogen (ER) and
progesterone (PgR) receptor assays. uPA was determined using a classical ELISA method (Imubind; American Diagnostica) and a novel
automatic immunoluminometric assay (Lia; Sangtec Medical). The uPA Imubind method revealed about twice as much uPA antigen (median
0.75 ng mg-1 protein) as the uPA Lia method (median 0.38 ng mg-1 protein). The correlation coefficient between the two methods was
acceptable (r = 0.81), but the two techniques are not interchangeable. Univariate analyses confirmed the poor outcome of patients whose
tumours contained large amounts of uPA, regardless of the technique used. Multivariate analyses showed that uPA Imubind and uPA Lia
values were both strong independent prognostic factors.
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Evidence has accumulated that invasion and metastasis by solid
tumours require the action of tumour-associated proteases, which
promote the dissolution of the surrounding tumour matrix and
basement membranes. In several independent studies of a variety
of cancer types, i.e. breast (Dano et al, 1985; Duffy et al, 1988),
colorectal (Ganesh et al, 1994; Skelly et al, 1995), lung (Oka et al,
1991), ovary (Kuhn et al, 1994), gastric (Nekarda et al, 1994; Cho
et al, 1997) and bladder cancer (Hasui et al, 1992), high levels of
the serine protease urokinase-type plasminogen activator (uPA)
antigen in tumour extracts were associated with rapid disease
progression and poor prognosis. In this study of 499 primary
breast cancer tumours, we used two different assay methods for
uPA antigen, in order to compare an enzyme-linked immunoassay
(uPA Imubind; American Diagnostica) with a new automatic
immunoluminometric assay (uPA Lia; Sangtec Medical), to assess
the relationships between uPA values and clinical and histological
factors and to evaluate the prognostic value ofthe two methods in
multivariate analyses.
MATERIALS AND METHODS
Patients
The study group consisted of499 breast cancer patients treated at
the Centre Rene Huguenin (CRH) between 1981 and 1989. The
median age was 58 years (range 24-84 years). Patients were
selected according to the following criteria: (1) primary, unilateral
breast tumour; (2) full follow-up at CRH; (3) previously untreated,
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without evidence of metastatic disease or any other malignant
tumour at the time ofdiagnosis; (4) surgery as the first treatment;
and (5) complete clinical, histological and biological information,
especially concerning hormone receptors and antigen levels of
uPA measured in cytosols by the two methods. All tumours were
graded by a method based on the criteria of Scarff-Bloom-
Richardson (Bloom and Richardson, 1957). The MSBR grade is a
simple rearrangement of the two nuclear scores of the SBR grade
(Le Doussal et al, 1989). Follow-up ranged from 385 days to 15
years, with a median of 6 years. A total of 235 patients (47%)
underwent partial mastectomy with axillary lymph nodeclearance,
and 263 patients (53%) had a modified radical mastectomy.
Adjuvant post-operative locoregional radiation was given to 219
(44%) patients. Adjuvant chemotherapy was given to 206 patients
(41%) and adjuvant hormonal therapy to 202 patients (40%).
Clinical, radiological and biological tests were performed every 3
months for the first 2 years and yearly thereafter. At the time of
analysis, 151 patients (30%) had relapsed (local recurrence and/or
distant metastasis), 117 (23%) had distant metastasis and 80 (16%)
had died of cancer. Overall survival (OS), disease-free survival
(DFS) and metastasis-free survival (MFS) were defined as the
time between diagnosis and the occurrence ofbreast cancerrelated
death, the first relapse (local recurrence and/or distant metastasis)
and the first distant metastasis, respectively, or the end of the
study. Patients who died ofcauses unrelated to breast cancer were
considered as censored at the time of death. Hereafter, 'death'
refers to breast cancer-related death.
Tissue extracts
Tumour specimens were obtained at surgery, selected by the
pathologist and stored in liquid nitrogen. For extraction, tissue
pieces (mean ± s.d., 0.22 g ± 0.06) were pulverized in liquid
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nitrogen in 10 mm Tris-HCl buffer pH 7.4 containing 1.5 mM
EDTA, 0.5 mm dithiothreitol, 5 mM sodium molybdate and 10%
glycerol. The suspension was centrifuged at 100 000 g at 40C for
60 min. The cytosols were aliquoted and stored in liquid nitrogen
until use (maximum 6 months).
uPA Imubind assay
uPA Imubind was determined using an enzyme-linked
immunosorbent assay (ELISA) method (American Diagnostica,
Greenwich, CT, USA). It detects uPA in the proenzyme form, the
active two-chain uPA, uPA bound to its receptor (uPAR) and uPA
in complex with the two inhibitors, PAI-I and PAI-2. Assays were
all performed in duplicate. UPA levels were expressed in ng mg-'
protein. The detection limit is 10 pg ml-1 diluted cytosol. The stan-
dard curve (sc-uPA) ranged from 0 to 1 ng ml-. Samples ofpooled
breast tumour cytosols were analysed for precision. The within-
assay coefficient ofvariation (CV) is 9.2% and the between-assay
CV is 11.6%.
uPA Lia assay
The uPA Lia assay (uPA LIA; AB Sangtec Medical, Bromma,
Sweden) (Ferno et al, 1996) is based on tubes precoated with
mouse monoclonal anti-uPA antibody and a detection reagent
containing monoclonal antibodies conjugated to an isoluminol
derivative. It detects uPA in the proenzyme form, the active two-
chain uPA, uPA bound to its receptor (uPAR) and uPA in complex
with the inhibitor PAI-1. Catalyst reagents that induce light emis-
sion from the bound isoluminol derivative are added automatically
in the luminometer, and the light signal is read immediately for5 s.
The signal is measured in relative light units (RLUs). The amount
ofuPA in the cytosol is expressed as uPA ng mg-' protein; all incu-
bations were performed in duplicate. The standard curve (HMW
uPA) ranged from 0 to 40 ng ml-l. The detection limit was below
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Figure 1 Relation between uPA Imubind and uPA Lia, with the line of
equality and the regression values line
5 pg ml-' diluted cytosol. Pooled breast tumour cytosol extracts
were analysed for precision. The within-assay CV is 3% and the
between-assay CV is 8.3%.
Protein assay
The Pierce method (Wiechelman et al, 1988) was used for protein
assay (mean 2.40 mg ml-'). The concentrations ofreagents used in
the extraction procedure do not interfere with the BCA assay.
Standard bovine serum albumin, fraction V (BSA; Pierce
Rockford, IL, USA) (2 mg ml-1 in 0.9% aqueous NaCl solution)
was used for calibration. Samples and standards were both assayed
in duplicate.
Oestrogen (ER) and progesterone (PgR) receptor
assays
ER and PgR receptors were assayed until 1988 using a dextran-
coated charcoal method according to EORTC guidelines (EORTC
Breast Co-operative Group, 1980). A total specific hormone-
binding capacity of 2 10 fmol mg' cytosol protein was classified
as positive, and less than 10 fmol mg-' as negative. After 1988,
we used an ELISA method (ER-EIA Monoclonal, PgR-EIA
Monoclonal; Abbott Laboratories, Abbott Park, IL, USA) with a
cut-offof 15 fmol mg-1 cytosol protein.
Statistical methods
The Bland and Altman method (1986) was used to compare the
uPA Lia assay with the uPA Imubind assay. This approach is based
on a graphical technique and simple calculation. Continuous vari-
ables were transformed into binary variables. For uPA Imubind
and uPA Lia variables and according to each outcome (OS, DFS
and MFS), the cut-off points were determined by using the
'minimum P-value' (Hilsenbeck et al, 1996) method, which
chooses the cut-off points that minimize the P-value relating the
variables to outcome measure. The search was done within a selec-
tion interval defined by excluding the 5% smallest and largest
values of the variables as potential cut-off points. Because of the
well-known problem of multiple testing, the observed minimum
P-value was corrected (Hilsenbeck et al, 1996). Differences in the
distribution of characteristics between patient subgroups were
analysed using the chi-square test. Actuarial OS, DFS and MFS
rates were computed using the method of Kaplan and Meier
(1958) and compared using the log rank test (Peto et al, 1977).
Multivariate analyses based upon the Cox proportional hazards
model (Cox, 1972) were performed to identify the most significant
factors related to OS, DFS and MFS. A significance level of 5%
was chosen as the criterion for entering factors in the Cox model.
The results of the multivariate analyses are expressed in terms of
relative risks (RR) derived from the estimated regression coeffi-
cients along with their 95% confidence interval (CI).
RESULTS
Comparison of the two uPA assay methods
The two uPA methods (Imubind and Lia) were performed with
their own respective standard type (sc-uPA and HMW uPA respec-
tively). UPA Imubind levels ranged from 0.00 to 7.22 ng mg-1
protein (median 0.75; mean ± s.d. 1.0 ± 0.92) compared with 0.01
British Journal ofCancer (1998) 77(9), 1495-1501
...................... I...................
0CancerResearch Campaign 1998Urokinaseplasminogen activatorin breastcancer 1497
d+2s = 75.9E
C " .t .;.;.;-.: : ........ ,* . d=-46.455
X -100..
E
d-2s=-168.E ~-200'
0
x
0- -300
c
a -400
-500
-600 0 0 6
. . . . 26.
. . 360 40.
. ... . . 0 100 200 300 400
Average uPA x 100 by twotechniques
Figure 2 Difference against mean for uPA data. d= difference in uPA
(x 100); s = standard deviation of the differences (x 100)
to 2.81 ng mg-' protein in the Lia method (median 0.38;
32 mean ± s.d. 0.53 ± 0.46). Figure 1 shows the scatterplotofthe data,
the plot ofthe regression line and the line ofequality on which all
points would lie ifthe two methods gave exactly the same reading
every time. The correlation coefficient between the two methods
was r= 0.81 (P <0.0001). This coefficient measures the strength of
the relation between the two ELISAs, not the agreement between
372 them. Perfect agreement is only obtained if the points in Figure 1
lie along the line ofequality, but a perfect correlation is obtained if
the points lie along the regression line. This was not the case in this
study, as not all the data points clustered near either of the two
lines. A plot ofthe differences between uPA Lia and uPA Imubind
values against their mean may be more informative. Figure 2
displays the relative lack of agreement between the two assays.
This lack of agreement can be summarized by computing the bias,
estimated by the mean difference (d x 100) and the standard devia-
tion ofthe differences (s x 100). Ifthere is a consistent bias, we can
adjust for it by subtracting dfrom the uPA Imubind value. Ifdiffer-
ences within d ± 2s are not clinically important, the two methods 500
are interchangeable. According to our data, the mean difference
(d x 100) (uPA Lia - uPA Imubind) is 46.455 ng mg-' protein and
(s x 100) is 61 ng mg-' protein. The 'limits ofagreement' are d- 2s
= - 168.872 ng mg-' protein and d+2s = 75.962 ng mg-' protein.
Table 1 Relation between uPA Imubind, uPA Lia and patient characteristics along with the coding of variables in Cox analyses
Variables No. of patients uPAlmubind uPA Lia
0: < 1.84 1: > 1.84 P-valuea 0: < 0.20 1: [0.20-1.14] 2: > 1.14 P-value
All 499 425 74 138 310 51
Age NS NS
0: < 50 years 123 100 23 31 77 15
1: > 50 years 376 325 51 107 233 36
Menopausal status NS NS
0: Premenopausal 151 125 26 41 93 17
1: Post-menopausal 348 300 48 97 217 34
Clinical tumour size < 0.0001 < 0.0001
0: < 25 mm 186 172 14 72 105 9
1: >25 mm 313 253 60 66 205 42
Surgical tumour size 0.002 < 0.0001
0: <20 mm 211 192 19 79 119 13
1: > 20 mm 288 233 55 59 191 38
ER status ns 0.005
0: Positive 368 316 52 106 234 28
1: Negative 131 109 22 32 76 23
PgR status 0.02 0.001
0: Positive 286 253 33 83 186 17
1: Negative 213 172 41 55 124 34
SBR grade 0.05 0.02
0:1 49 45 4 18 29 2
1:11 309 268 41 93 188 28
2:111 141 112 29 27 93 21
MSBR grade < 0.0002 < 0.0001
0:1 169 158 11 68 93 8
1:11 330 267 63 70 217 43
Nodal status 0.03 NS
0: 0 233 197 36 72 137 24
1: 1-3 177 159 18 45 120 12
2: > 3 89 69 20 21 53 15
aChi-square test. NS, not significant (P > 0.05).
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Table 2 Results of univariate and Cox multivariate analyses in 499 breast cancer tumours
Overall survival Disease-free survival Metastasis-free survival
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Variables P-value P-value RR- (CI)b P-value P-value RR (Cl) P-value PLvalue RR (Cl)
Nodal statusc <0.0001 <0.0001 3.93(2.5-6.14) <0.0001 <0.0001 2.34(1.66-3.31) <0.0001 <0.0001 2.50 (1.7-3.68)
uPA Lia < 0.0001 NSd < 0.0001 < 0.0001 1.98(1.49-2.64) < 0.0001 < 0.0001 1.78 (1.23-2.59)
uPAImubind <0.0001 <0.0001 3.13(1.96-5.01) <0.0001 NS <0.0001 0.04 1.67(1.03-2.71)
Clinical size 0.0002 0.008 2.11(1.17-3.80) < 0.0001 0.006 1.69(1.15-2.48) 0.0002 0.03 1.58 (1.01-2.47)
Surgical size < 0.0001 NS < 0.0001 NS < 0.0001 NS
MSBR grade <0.0001 NS 0.0002 NS <0.0001 0.02 1.64 (1.01-2.66)
SBR grade < 0.0001 NS < 0.0001 NS < 0.0001 NS
ER status 0.006 0.003 2.00(1.27-3.14) NS NS NS NS
PgR status 0.0009 NS 0.008 NS 0.0008 NS
Age NS NS NS NS NS NS
Menopausal status NS NS NS NS NS NS
Chemotherapyc NS NS NS NS NS NS
Hormonal therapye NS NS NS NS NS NS
aRR, relative risk. bCl, 95% confidence interval. cNodal status and treatments are defined as . three versus > three involved nodes, and no
versus yes respectively. For the coding of the othervariables, see Table 1. dNot significant (P > 0.05), likelihood ratio test for inclusion of the
variable in the model.
Thus, the uPA Lia value (x 100) may be 169 ng mg-' protein below
or 76 ng mg-' protein above the uPA Imubind value, which would
be unacceptable for clinical purposes. This lack ofagreement is by
no means obvious in Figure 1. Furthermore, the standard error ofd
is 0.027 and the 95% CI forthe bias is (-0.52, -0.41). The standard
error ofd ± 2s is 0.047, while the 95% CI ofd - 2s and d + 2s are
(-1.78, -1.60) and (0.67, 0.85) respectively. These intervals are
wide, reflecting the strong variation ofthe differences. They reveal
discrepancies between the two methods and show that they cannot
be used indifferently.
Cut-off points for uPA Imubind and uPA Lia
In uPA Imubind, the minimumP-value was obtained at acut-offof
1.84 ng mg-' protein when failure was taken as death, metastasis
or relapse. The corrected P-value reached a value of < 0.0001,
whatever the end point for failure, and when the range ofpossible
cut-off points was restricted to the interval between the 5% and
95% quantiles of the uPA Imubind value. The same analysis was
used to set the cut-off points for uPA Lia at 0.20 ng mg-' protein
and 1.14 ng mg-' protein, with a corrected P-value of < 0.0001,
whatever the end point for failure.
Relation between uPA Imubind, uPA Lia and other
patients characteristics (Table 1)
Whatever the technique, there was no significant link between the
level of uPA and age or menopausal status. The uPA imubind
value was not related to ER status, but the majority of tumours
(76%) with uPA Lia < 1.14 ng mg-' protein were ER+. Tumours
with high uPA values (Imubind > 1.84 or uPA Lia > 1.14) were
more often PgR-. Tumours with high uPA values (Imubind > 1.84
or uPA Lia > 1.14) were more often SBR II or III or MSBR grade
II. The majority of large tumours (clinical size > 25 mm, surgical
size > 20 mm) contained high uPA levels by both methods. The
majority (82%) oftumours larger than 25 mm contained high uPA
levels by both methods. Although the frequency of patients with
high uPA Imubind or uPA Lia values was approximately the same
in the node-negative and node-positive subgroups, about 47% of
uPA levels (uPA Imubind < 1.84 oruPA Lia < 0.20) were observed
in node-negative patients.
Univariate analyses (Table 2)
Age and menopausal status were not significantly related to any of
the three outcomes. Overall survival was influenced by ER status,
but there was no significant difference in DFS or MFS. However,
all the remaining factors seemed to affect OS, DFS and MFS when
examined individually. In particular, high levels of uPA Imubind
(> 1.84) and uPA Lia (> 1.14) were significantly associated with
poorer overall survival and shorter relapse-free or metastasis-free
survival. Figure 3 displays the survival curves of uPA determined
by the two techniques. There are significant differences between
curves 1 (uPA Imubind < 1.84) and 2 (uPA Imubind > 1.84)
(P <0.0001), 3 (uPA Lia <0.20) and 4 (uPA Lia [0.20-1.14])
(P<0.001), and between curves 4 and 5 (uPA Lia> 1.14)
(P <0.00001), whatever the outcome.
Multivariate analyses
All the variables listed in Table 1, together with adjuvant treat-
ments (hormonal therapy and chemotherapy) were candidates in
the multivariate Cox regression model for their relationships with
OS, DFS and MFS.
Overall population
The results of multivariate analyses of499 breast cancer tumours
using the Cox model are presented in Table 2. The prognostic
factors independently associated with shorteroverall survival were
nodal status (> 3 involved nodes), uPA Imubind (> 1.84), clinical
tumour size (> 25 mm) and ER negativity. Three factors were
significantly related to DFS with the poorest prognosis: nodal
status (> 3 involved nodes), uPA Lia (> 1.14) and clinical tumour
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Table 3 Results of Cox multivanate analyses in the node-negative and
node-positive subgroups of patients
Subgroup Outcome Variable P-value RR- (CI)b
Node-negative
OS uPA Lia 0.005 2.75 (1.35-5.57)
DFS uPA Lia 0.0002 2.33 (1.50-3.62)
MFS uPA Lia < 0.0001 3.73 (2.17-6.42)
Node-positive
OS Nodal statusc < 0.0001 3.21 (1.85-5.55)
uPA Imubind <0.0001 3.26 (1.86-5.72)
ER status 0.002 2.25 (1.33-3.81)
Clinical size 0.02 2.23 (1.04-4.78)
DFS Nodal status < 0.0001 2.19 (1.45-3.31)
uPA Lia 0.0002 1.70 (1.18-2.43)
MSBR grade 0.003 2.21 (1.17-4.20)
Clinical size 0.008 2.00 (1.15-3.46)
MFS Nodal status < 0.0001 2.52 (1.59-3.98)
uPA Imubind 0.0008 2.42 (1.44-4.08)
Clinical size 0.005 2.17 (1.19-3.98)
ER status 0.03 1.71 (1.07-2.73)
aRR, relative risk. bCl, 95% confidence interval. cNodal status is defined as
1-3 versus > 3 involved nodes in the node-positive group. For the coding of
the other variables, see Table 1.
size (> 25 mm). With regard to MFS, the most important adverse
prognostic factors were nodal status (> 3 involvednodes), uPA Lia
(> 1.14), uPA Imubind (> 1.84), clinical tumour size (> 25 mm)
and MSBR grade II.
Nodal status subgroups
The results ofCox multivariate analyses in the node-negative and
node-positive subgroups are presented in Table 3. In the subgroup
of patients free from lymph node involvement, uPA Lia (> 1.14)
was the only important adverse prognostic factor for OS, DFS and
MFS. In the patients with node involvement, nodal status (> 3
involved nodes), uPA Imubind (> 1.84), clinical tumour size
(> 25 mm) and ER negativity were significantly associated with
shorter overall survival. With regard to DFS, the most important
adverse prognostic factors significantly related to the risk of
relapse were nodal status (> 3 involved nodes), uPA Lia (> 1.14),
MSBR grade II and clinical tumour size (> 25 mm). Four factors
were independently associated with shorter MFS: nodal status
(> 3 involved nodes), uPA Imubind (> 1.84), clinical tumour size
(> 25 mm) and ER status.
DISCUSSION
Tumour invasion, which is associated with destruction of the
basement membrane and subcellular matrix (Duffy et al, 1987),
appears to be caused by the coordinated action of proteases
secreted by malignant cells and the stroma. Urokinase and its
inhibitors have been proposed as new prognostic factors in breast
cancer (Duffy et al, 1990; Janicke et al, 1990; Foekens et al, 1992;
Spyratos et al, 1992; Bouchet et al 1994; Foekens et al, 1995).
However, their use for this purpose can only be envisaged once the
results obtained with different assay methods have been compared.
The prognostic value of uPA assay by the Imubind method has
been demonstrated (Foekens et al, 1992; Janicke et al, 1991,
1994). The aim of our work was to test a new automated ELISA
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Table 4 Published distributions of uPA (ng mg-1 cytosolic protein) in breast tumours
Authors Range Median Mean Cut-off Median Methods Triton
follow-up X-100
(months) extract
Janicke et al. (1990) (0.07-11.90) 2.60 3.20 3.49 25 Imubind Yes
Foekens et al. (1992) (0.01-9.80) 0.70 1.00 1.15 60 Imubind No
Janicke et al. (1994) (0.13-15.17) 2.32 3.06 2.97 30 Imubind Yes
(0.02-9.08) 1.07 1.67 1.56 30 Imubind No
Femoet al. (1996) (0.00-3.19) 0.40 0.62 42 Lia No
Our study (0.00-7.22) 0.75 1.00 1.84 72 Imubind No
(0.01-2.81) 0.38 0.53 (0.20,1.14) 72 Lia No
method for uPA and to compare the results obtained with the
Imubind method on the same breast cancer cytosols. The cytosols
were prepared under identical conditions to those used for
hormone receptor assays. The LiauPA method is simple, rapid and
highly reproducible. The between-run coefficient of variation,
based on a pooled sample, was lower in the Lia than in the
Imubind method (8.3% and 11.6% respectively). Table 4 compares
recently published breast tumour cytosol uPA values obtained
using the Imubind and Lia methods in the presence and absence of
Triton X-100 in the homogenization buffer (Schmitt et al, 1991).
Our Imubind results are very similar to those of Foekens et al
(1992) and Janicke et al (1994) who, like us, did not use an ionic
detergent. The results obtained with the Lia uPA method on all the
cytosols were similar to those reported by Ferno et al (1994, 1996)
using the same method. In our study, the median value obtained in
the Lia method was below that obtained in the Imubind method,
confirming previous reports.
There was a good correlation between the two methods, but the
correlation coefficient is not a reliable basis for demonstrating the
equivalence of two methods (Bland and Altman, 1986). UPA
values depend on the source and composition of the ELISA kit.
Commercial antibodies have different specificities and affinities
for the multiple molecular forms ofurokinase, i.e. the single chain
of the proenzyme (pro-uPA), the low molecular weight chain
(LMW-uPA) and the high molecular weightchain (HMW-uPA). In
addition, pro-uPA and HMW-uPA can be complexed to the uPA
receptor (uPAR). HMW-uPA, LMW-uPA and receptor-bound uPA
(uPA-uPAR) can also be complexed to the two main inhibitors of
uPA (PAI-I and PAI-2). Thus, the uPA present in cytosols occurs
in a variety of structures and molecular weights. The antibodies
provided with the two assay kits also have different compositions
(Table 4). It is not, therefore, surprising that the observed antigen
level differs when measured in the same cytosol extract, especially
as the proteolytic cascade involves proenzymes and enzymes,
receptors, inhibitors and antibodies with different specificities.
We used the approach ofHilsenbeck and Clark (1996) to choose
the cut-offs; consequently, uPA Imubind values were
dichotomized, while uPA Lia values were divided into three
groups. The positions ofthe curves in Figure 3 justify this choice.
For example, 75% of the 51 cases in group 5 (uPA Lia > 1.14)
were included in group 2 (uPA Imubind > 1.84), and 22 (81%) out
of the 27 patients with metastases in group 5 (uPA Lia > 1.14)
were included in group 2 (uPA Imubind > 1.84). Whatever the
method (Imubind or Lia) and irrespective ofthe cut-offs we deter-
mined, respectively 15% and 10% of patients with high uPA
values had a poor prognosis. The corresponding proportions of
patients were higher (26%, 32% and 33% respectively) in the
studies by Janicke et al (1990), Foekens et al (1992) and Ferno et
al (1996). These differences can beexplainedbyinequalities in the
size of the populations studied and in the median follow-up
periods (12.5 months, 48 months and 42 months respectively; 72
months in our study).
In the multivariate analyses, the predictive value of uPA
remained high and independent ofconventional predictive factors,
regardless of the assay method (Imubind or Lia). However, high
uPA Lia values were chiefly associated with shorter disease-free
survival and metastasis-free survival in the overall population. In
the subgroup of patients free of lymph node involvement, a high
uPA Lia value was the only important adverse prognostic factor
for OS, DFS and MFS. These results support those of Kute et al
(1994) and Janicke et al (1993).
Automated urokinase assay by the Lia method is thus feasible,
and the predictive value of this marker is valid regardless of the
method used. Whether one or several markers should be used to
detect tumour invasion remains to be settled. Imubind ELISA
methods for uPA, uPAR and the two inhibitors (PAI-I and PAI-2)
are being assessed. It is probable that two or more markers will
have to be combined to obtain a reliable prognostic score in breast
cancer. Assay techniques formarkers ofmetastatic disease mustbe
perfectly standardized (Schmitt et al, 1991; Janicke et al, 1994;
Romain et al, 1995; Benraad et al, 1996; Bouchet et al, 1996;
R0nne et al, 1995) if they are to be of use for diagnosis and the
decision to give adjuvant therapy.
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